GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data details the technical […]
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), […]
“One of the reasons we perform single-cell approaches is they allow us to pick up subtle differences that would be missed with more conventional tools,” says David S. Johnson, PhD, CEO and co-founder of GigaGen, a company that specializes in microfluidics and molecular genomics. Two GigaGen platforms, Surge and Magnify, can facilitate the development of […]
GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma. GigaGen Inc. plans to submit an IND for its COVID-19 treatment, GIGA-2050, by year-end. It calls GIGA-2050 a recombinant hyperimmune product, and said it is akin to recombinant convalescent sera. GigaGen showed […]
A South San Francisco biotech firm has come up with a way to make a COVID-19 therapy without relying on repeat antibody donors using a new class of drugs called “recombinant hyperimmunes.” Ken Bastida reports. (8-10-20) Watch the tv segment.
Blood collected from survivors of COVID-19 has been used to identify antibodies against the disease, which have been turned into experimental drugs to fight it. But it’s not an easy process. So back in March, San Francisco startup GigaGen decided to test a technology it developed to rapidly identify disease-fighting antibodies against SARS-CoV-2, the virus […]
Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences selected from 16 exceptional […]
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today a new submission to bioRxiv, titled, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs.” In this study, GigaGen presents a novel […]
SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, today announced that it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place on August 4-5, 2020. Read the full press release.
Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients. Read the full story.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19. Read the full story.
Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow. GigaGen, which is backed by Grifols, is a more recent arrival, and its cell-based recombinant polyclonal immunoglobulin production system is at an earlier stage of development. It involves […]
It’s not just people and animals that can produce antibodies. Scientists now have the technology to build what are essentially molecular copying machines that can theoretically churn out large volumes of the antibodies found in recovered patients. At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying […]
Scientists worldwide are racing to develop more than 160 new drug and vaccine candidates to combat the pandemic, GEN reports in a comprehensive new A-List Read the full story.
Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment The race to find a treatment for COVID-19 is in full swing as researchers in labs across the world attempt to unravel the unique properties of this disease, and find ways to neutralize it. To aid in the effort, […]
Companies say it is too soon to know how many patients can be treated from one plasma donation, but it is likely no more than a few, at best. Emergent is hoping to avoid potential delays in plasma collection by also producing hyperimmune globulins in horses vaccinated with whole or partial bits of SARS-CoV-2. SAB […]
Biotechnology company GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment. The therapy reproduces whole antibody repertoires of recovered patients, including antibodies that block further replication of the novel coronavirus. Read the full story.
The company thinks it can scale up production of its recombinant polyclonal antibodies in early July, but an actual COVID-19 treatment may be several more months away. Read the full story.
GigaGen Announces Publication in the Peer-Reviewed Journal mAbs
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data details the technical […]
GigaGen Initiates Large-Scale Manufacturing of First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), […]
GEN: Drug Targets Identified More Discerningly
“One of the reasons we perform single-cell approaches is they allow us to pick up subtle differences that would be missed with more conventional tools,” says David S. Johnson, PhD, CEO and co-founder of GigaGen, a company that specializes in microfluidics and molecular genomics. Two GigaGen platforms, Surge and Magnify, can facilitate the development of […]
BioCentury: GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute
GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma. GigaGen Inc. plans to submit an IND for its COVID-19 treatment, GIGA-2050, by year-end. It calls GIGA-2050 a recombinant hyperimmune product, and said it is akin to recombinant convalescent sera. GigaGen showed […]
KPIX-TV (CBS): Bay Area Biotech Company Takes New Approach in COVID-19 Treatment
A South San Francisco biotech firm has come up with a way to make a COVID-19 therapy without relying on repeat antibody donors using a new class of drugs called “recombinant hyperimmunes.” Ken Bastida reports. (8-10-20) Watch the tv segment.
Fierce Biotech: GigaGen’s polyclonal antibody against COVID-19 outperforms plasma in lab tests
Blood collected from survivors of COVID-19 has been used to identify antibodies against the disease, which have been turned into experimental drugs to fight it. But it’s not an easy process. So back in March, San Francisco startup GigaGen decided to test a technology it developed to rapidly identify disease-fighting antibodies against SARS-CoV-2, the virus […]
BioSpace: GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy
Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences selected from 16 exceptional […]
GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today a new submission to bioRxiv, titled, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs.” In this study, GigaGen presents a novel […]
GigaGen to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, today announced that it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place on August 4-5, 2020. Read the full press release.
BioPharm International: Plasma-Based Antibody Therapies Battle Against COVID-19
Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients. Read the full story.
San Francisco Business Times: Biotech adapts to new working conditions in the age of Covid-19
Read the full story.
Drug Target Review: Intravenous immunoglobulins, hyperimmunes and pandemic viruses
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19. Read the full story.
Nature Biotechnology: Convalescent serum lines up as first-choice treatment for coronavirus
Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow. GigaGen, which is backed by Grifols, is a more recent arrival, and its cell-based recombinant polyclonal immunoglobulin production system is at an earlier stage of development. It involves […]
TIME: Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
It’s not just people and animals that can produce antibodies. Scientists now have the technology to build what are essentially molecular copying machines that can theoretically churn out large volumes of the antibodies found in recovered patients. At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying […]
WGNO-TV (ABC): Coronavirus Survivors Needed: New Orleans Doctor is collecting blood samples from survivors to make treatment
Watch the tv news report.
GEN: Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development
Scientists worldwide are racing to develop more than 160 new drug and vaccine candidates to combat the pandemic, GEN reports in a comprehensive new A-List Read the full story.
The Lens: Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment
Recovered COVID-19 patients in New Orleans area donate blood to California biotech firm working on treatment The race to find a treatment for COVID-19 is in full swing as researchers in labs across the world attempt to unravel the unique properties of this disease, and find ways to neutralize it. To aid in the effort, […]
Chemical & Engineering News: Searching for a coronavirus cure in the blood: Scientists look to convalescent plasma, hyperimmune therapy, and monoclonal antibodies to treat COVID-19
Companies say it is too soon to know how many patients can be treated from one plasma donation, but it is likely no more than a few, at best. Emergent is hoping to avoid potential delays in plasma collection by also producing hyperimmune globulins in horses vaccinated with whole or partial bits of SARS-CoV-2. SAB […]
Pharmaceutical Technology: GigaGen works on recombinant polyclonal antibody against Covid-19
Biotechnology company GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment. The therapy reproduces whole antibody repertoires of recovered patients, including antibodies that block further replication of the novel coronavirus. Read the full story.
San Francisco Business Times: Peninsula biotech readies attack on COVID-19 — all it needs now is more cash and recovered patients’ blood
The company thinks it can scale up production of its recombinant polyclonal antibodies in early July, but an actual COVID-19 treatment may be several more months away. Read the full story.